Concord Biotech Ltd Q4 FY26 Earnings Call: Summary, Management Commentary & Outlook

Concord Biotech Ltd held its Q4 FY26 earnings call on May 29, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline Financials for the Just-Completed Fiscal Year

• FY26 total revenue of ~Rs.1,036 Cr(80:20 API:Formulation mix), reflecting a 12% YoY de-growth; Q4 FY26 alone saw a 24% de-growth.
• Reported EBITDA of Rs.367 Cr(35% margin); adjusted for Rs.75 Cr of unabsorbed opex from injectables and CDMO ventures, adjusted EBITDA margin stood at 39% for FY26 and 40.4% for Q4 FY26.
• Profit after tax declined 30%to Rs.260 Cr in FY26, pressured by revenue headwinds and new-venture setup costs.
• Zero-debt balance sheet with Rs.414 Cr cashas of 31 March 2026; capex of Rs.65 Cr and operating cash flow of Rs.267 Cr (73% CFO-to-EBITDA conversion) during FY26.
• Manufacturing capacities across all four unitssupport a peak revenue potential of approximately Rs.3,000 Cr, with no material capacity constraints identified.

Management Guidance for FY 2026-2027 and Beyond

• FY27 growth guided "slightly better" than historical ~18%— management expects strong outperformance in FY 2026-2027, with robust visibility for H1 FY27 and growth anticipated from Q1 itself.
• Middle East tender (~Rs.25 Cr Q3 FY26 impact)— API supplies are gradually resuming in FY27; formulation tender visibility remains unclear, with the prior impact stemming from regional war conditions.
• EU supply restrictions (~3 months of FY26)due to delays in "written confirmation approvals from Sedisco/EDQM"; management noted a gradual, not immediate, recovery of deferred revenues.
• US procurement slowed in H1 FY26on tariff uncertainty but improved in H2; customers are now shifting to de-risk supply chains, supporting near-term order momentum.
• US Veterans Affairs tender remains on holdas the related tender was not finalized; Stellon Biotech (US subsidiary) has orders placed for H1 FY27 supplies.
• API supplies to two innovator companies commenced; fusidic acid commercialized with limited competition; CDMO customer discussions are in advanced stages for potential uplift in FY27.

API vs Formulation, Domestic vs Export, and Molecule Mix

• API revenue of Rs.829 Cr in FY26(12% de-growth); formulation revenue declined 13% in FY26. Q4 FY26 saw API de-growth of 27% and formulation de-growth of 8%.
• Domestic revenue de-grew 15% in FY26vs export de-growth of 9%; management attributed the export decline to indirect sales (Indian manufacturers supplying US markets) and Middle East supplies being classified as domestic formulations.
• Formulation decline driven by geopolitical issuesaffecting international business; all other regions (domestic, US business) grew within the formulation segment.
• Top five molecules in FY26 not considered representativefor the base portfolio; FY27 growth is expected from oncology and anti-infective segments, including Nystatin and fusidic acid initial supplies.
• API:Formulation mix expected to remain ~80:20 (±2-3%)in FY27, consistent with prior years; gross margins expected to sustain near historical levels.
• CDMO (third-party IP) revenue at ~1-4% of sales in FY26, primarily API; one opportunity at advanced discussion stage that could meaningfully change the contribution in FY27.

EBITDA Drivers, Energy Costs, and New-Venture Path to Break-Even

• No specific EBITDA margin guidance for FY27; management cited a 1-1.5% positive impact from lower power costs and operating leverage from Stellan Biotech and injectables (expenses already built up in FY26).
• Power and fuel constitute ~20% of total costsin FY27; LPG/furnace oil accounts for ~50% of that (~10% of total costs). Normalisation of LPG/furnace oil prices alone could improve EBITDA margin by 1-1.5%.
• Government restrictions on industrial fuel usein early April FY27 disrupted supply chains; management confirmed shortages have been resolved, but elevated pricing persists.
• Energy savings from renewable energy guided at 100-150 bpsmargin improvement; combined with reduced losses in injectables and CDMO, total margin improvement could reach 200 bps or more in FY27.
• Rs.75 Cr of additional opex from injectables (Rs.38 Cr) and CDMO (Rs.10 Cr)was not absorbed in FY26; adjusted margins would have been "north of 40%" without these costs.
• Operating leverage from injectables and CDMOexpected to kick in during FY27; full break-even is targeted by FY27-2028 (next fiscal year).

Asset Utilisation, Capex Plans, and Inventory Normalisation

• Capacity utilisation as of Q4 FY26:Unit 1 at 77% (optimal), Unit 2 at 30%, Unit 3 at 53%; Unit 4 (injectables) received WHO GMP certification and has commenced sales.
• Maintenance capex of Rs.20-30 Cr per annumguided for FY28 (FY 2027-2028); no major new project requirements currently identified. Management stated "current capacity is adequate to support turnover of Rs.3,000 crores; no material capex needed for the next 4–5 years" beyond small debottlenecking of Rs.50-100 Cr over 2-3 years.
• Capital work in progress of Rs.79.3 Cras of the FY26 balance sheet, attributed to the soft gel facility setup and modifications for an innovator company project.
• Inventory days rose to 480 in FY26from 280 in FY25; absolute inventory increased to Rs.326 Cr from Rs.240 Cr, driven by staggered customer procurement and higher fermentation utilisation.
• Elevated inventory expected to unwind during H1 FY27; management sees "low probability of inventory write-off from a formulation standpoint," with Middle East inventory primarily API to avoid shelf-life issues.
• Steady-state working capital intensity over FY27-FY29expected to be in line with historical levels, given the API-heavy business mix and normalisation of procurement patterns.